about
Murine pressure overload models: a 30-MHz look brings a whole new "sound" into data interpretation.Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodelingExperimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction.Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodelingNeovascularization Potential of Blood Outgrowth Endothelial Cells From Patients With Stable Ischemic Heart Failure Is Preserved.Gender-specific modulation of the response to arterial injury by soluble guanylate cyclase α1.Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction.Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury.Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.Preexisting antiadenoviral immunity and regional myocardial gene transfer: modulation by nitric oxide.Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries.Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion.Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy.Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction.Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment.Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury.Placental growth factor 2--A potential therapeutic strategy for chronic myocardial ischemia.Placental growth factor increases regional myocardial blood flow and contractile function in chronic myocardial ischemia.In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.[Possibilities for cardiovascular gene therapy]Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep modelEvaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)Effect of salt stress on fatty acid alterations in some strains of Dipodascopsis and Dipodascus sppNitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial
P50
Q30838476-B4866088-0830-4BFA-8545-2C5BB848AF08Q34634339-78DA2D20-E6DD-48D4-BC2D-5F9E50F74669Q35038117-D54765A7-7F6A-417A-889C-93C1C0EDB259Q36012729-A5670769-46B7-4F17-8069-EF53004F2B46Q36831811-6771782E-8CF5-4DF8-8B59-D1B3FE8D8D41Q37346565-CE6C048B-B605-4ADB-A441-3B60C8E710B3Q40125970-EA13EAE9-4E3A-4308-AF7D-968C7EF28341Q40161387-85ADD90A-446C-4C68-ACC9-E5783B8BAAD5Q43216284-2FA978EF-F426-4775-9FC2-30B9A7A2CECFQ44814453-39ABDEA9-17FC-4941-A648-74B409C8C646Q45858017-3C8560AF-24D3-45D8-B95C-915231DB71A8Q45870023-AC086C3C-4359-4D9F-845F-F457C5FE4533Q46888160-2DB99E09-E69F-4584-86FA-AE07F4D82598Q47273911-2BB9E911-F42B-42DB-B4EB-A0F84FC1C2DCQ48121800-7378F7D3-AD7F-4D19-A189-544A40434667Q48293024-0391052E-786D-4D05-A031-C12F1FFDA61DQ50553481-E0EE1887-135F-42FF-BA9A-4A3EB87D2FE4Q50885740-A2659FCD-79F8-455D-A750-62BBFC8854FBQ50906948-FFF7F529-FFD6-4E1D-989F-118ADB35C1EFQ50912382-67E30041-4DDE-4B77-AC3E-A3B442051142Q51838403-047C19F0-30FF-45F0-8D0B-3A4507C5D297Q53738361-E9CE1640-67CF-4829-AFC9-CD0D19F72049Q81924946-9DC34500-A972-4FD6-BDB8-467CAD303631Q83378526-51253AA8-502E-4533-B38E-6B17F931C3E8Q86867075-6C2F2B4C-B8DE-4945-97B8-429A26AB52D3Q87091998-FF7166AC-3497-4061-BBA7-6960ECD97A81Q88813571-C218C011-82B0-427F-93A8-9489C9282C3B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter Pokreisz
@ast
Peter Pokreisz
@en
Peter Pokreisz
@es
Peter Pokreisz
@nl
Peter Pokreisz
@sl
type
label
Peter Pokreisz
@ast
Peter Pokreisz
@en
Peter Pokreisz
@es
Peter Pokreisz
@nl
Peter Pokreisz
@sl
prefLabel
Peter Pokreisz
@ast
Peter Pokreisz
@en
Peter Pokreisz
@es
Peter Pokreisz
@nl
Peter Pokreisz
@sl
P106
P21
P31
P496
0000-0003-2810-9000